Northwestern University Feinberg School of Medicine

The Ken & Ruth Davee Department of Neurology

Clinical Trials

As part of an academic medical center, the Division of Movement Disorders at Northwestern University Feinberg School of Medicine (Feinberg) aims to improve the human health through scientific research.

About Clinical Trials
Clinical trials test or study drugs, surgical procedures, medical devices, or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

Division of Movement Disorders Clinical Trials
The following searchable list includes all the Division of Movement Disorders clinical trials currently looking for participants.

Contact Us
Please feel free to contact us with inquiries about any of our ongoing research.

Trials
National Parkinson Foundation Patient Registry
The purpose of this study is to collect registry data to examine the relationship between clinical symptoms and treatment in PD patients. Data collected will be used to describe differences in current treatment practices across many sites to evaluate tre…
The purpose of this study is to collect registry data to examine the relationship between clinical symptoms and treatment in PD patients. Data collected will be used to describe differences in current treatment practices across many sites to evaluate treatment and ultimately improve patient care.
• Patients diagnosed with idiopathic Parkinson’s Disease
• Must have established care with a movement disorder specialist at Northwestern
Simuni, TatyanaSimuni, Tatyana
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00014255
More Info

For more information on this study please contact us:

Friedeck, Heidi 312 503 1522
Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease
The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced,levodopa-responsive bilateral Parkinson's dise…
The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced,levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.
22-75 years old; Diagnosis of bilateral, idiopathic Parkinson's disease
Rosenow, Joshua MRosenow, Joshua M
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01839396 STU00094646
More Info

For more information on this study please contact us:

Coffey, Taylor 312 695 0482
Attention Bias: Testing a Potential Marker for the Diagnosis of Atypical Movement Disorders
The purpose of this study is to determine whether problems with attention lead to abnormal movements. The study involves a few thinking tests to determine if certain patterns of thinking or focusing can be ass…
The purpose of this study is to determine whether problems with attention lead to abnormal movements. The study involves a few thinking tests to determine if certain patterns of thinking or focusing can be associated with abnormal movements.
• Adult patients with a clinically established or documented psychogenic movement disorder
• Adult patients with a diagnosis of benign familial/ essential tremor as made by a movement disorder specialist
• Healthy adults who do not have any suspected or known neurologic movement disorders

Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00202673
More Info

For more information on this study please contact us:

Woods, Zakary 1-888-NU-STUDY
RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy
The purpose of this study is to evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonom…
The purpose of this study is to evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) Deficiency who have been previously stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension (NOH) (dizziness, light-headedness, or feelings that they are about to black out).
• 18 years or older and able to stand (with or without limited assistance)
• Clinical diagnosis of symptomatic orthostatic hypotension
Zadikoff, CindyZadikoff, Cindy
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT02586623 STU00202923
More Info

For more information on this study please contact us:

Rutkowski, Anna 1-888-NU-STUDY
Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers wil…
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD.
Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.
Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00203021
More Info

For more information on this study please contact us:

Brown, ZsaZsa 312 503 4121
A Phase IIb/III, Randomized, Double-Blind, Placebo-Controlled Trial of BHV-4157 in Adult Subjects with Spinocerebellar Ataxia
The purpose of this study is to evaluate the possible risks and effectiveness of the study drug BHV-4157 on ataxia symptoms in participants with spinocerebellar ataxia (SCA). …
The purpose of this study is to evaluate the possible risks and effectiveness of the study drug BHV-4157 on ataxia symptoms in participants with spinocerebellar ataxia (SCA). The effects of the study drug will be compared to placebo, an inactive substance made to look like an active medicine. Participants will either get the study drug or placebo.
• Age 18-75
• Ability to provide written informed consent
• Subjects with a known or suspected diagnosis of the following specific
hereditary ataxias: SCA1, SCA2, SCA6, SCA8 and SCA10;
1. Participants should have confirmed genotypic diagnosis from a CLIA-certified lab or a family member has had such testing
2. Participants must be willing to undergo genetic testing from a CLIA-certified lab if testing has not yet been previously done on the participant and a copy of results is not available for verification
• Ability to walk 8 meters without assistance (canes and other devices allowed)
• Minimum of 6 years of education and fluent in English
• Subjects must have adequate hearing, vision, and language skills to perform neuropsychiatric testing and interviews as specified in the protocol
• Subjects must be able to understand and agree to comply with the prescribed dosage regimens and procedures; report for regularly scheduled office visits; and reliably communicate with study personnel about adverse events and concomitant medications
Opal, PuneetOpal, Puneet
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT02960893 STU00204304
More Info

For more information on this study please contact us:

Tripathi, Priya Rakesh 1-888-NU-STUDY
Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) to Study Natural History and Genetic Modifiers in Spinocerebellar Ataxia (SCA)
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurolo…
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates.
• Age 18 and older
• Presence of symptoms and signs of ataxia
• Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member
• Willingness to participate in the study and ability to give informed consent.
Opal, PuneetOpal, Puneet
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT01060371 STU00204294
More Info

For more information on this study please contact us:

Brown, ZsaZsa 312 503 4121